Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Gary Gilliland

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Living Beings

Mice

Disorders

Chemicals & Drugs

Physiology

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Moellering Raymond E; Cornejo Melanie; Davis Tina N; Del Bianco Cristina; Aster Jon C; Blacklow Stephen C; Kung Andrew L; Gilliland D Gary; Verdine Gregory L; Bradner James E
Direct inhibition of the NOTCH transcription factor complex.
Haeno Hiroshi; Levine Ross L; Gilliland D Gary; Michor Franziska
A progenitor cell origin of myeloid malignancies.
Heinrichs S; Kulkarni R V; Bueso-Ramos C E; Levine R L; Loh M L; Li C; Neuberg D; Kornblau S M; Issa J-P; Gilliland D G; Garcia-Manero G; Kantarjian H M; Estey E H; Look A T
Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Gary Gilliland (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Moellering Raymond E; Cornejo Melanie; Davis Tina N; Del Bianco Cristina; Aster Jon C; Blacklow Stephen C; Kung Andrew L; Gilliland D Gary; Verdine Gregory L; Bradner James E
Direct inhibition of the NOTCH transcription factor complex.
Nature 2009;462(7270):182-8.
2009: Haeno Hiroshi; Levine Ross L; Gilliland D Gary; Michor Franziska
A progenitor cell origin of myeloid malignancies.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(39):16616-21.
2009: Heinrichs S; Kulkarni R V; Bueso-Ramos C E; Levine R L; Loh M L; Li C; Neuberg D; Kornblau S M; Issa J-P; Gilliland D G; Garcia-Manero G; Kantarjian H M; Estey E H; Look A T
Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(9):1605-13.
2009: Bernard Olivier A; Gilliland D Gary; Mercher Thomas
[The OTT-MAL fusion oncogene: another Notch in megakaryoblastic leukemia]
Médecine sciences : M/S 2009;25(8-9):676-8.
2009: Lane Steven W; Scadden David T; Gilliland D Gary
The leukemic stem cell niche: current concepts and therapeutic opportunities.
Blood 2009;114(6):1150-7.
2009: Wojiski S; Guibal F C; Kindler T; Lee B H; Jesneck J L; Fabian A; Tenen D G; Gilliland D G
PML-RARalpha initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(8):1462-71.
2009: Abdel-Wahab Omar; Mullally Ann; Hedvat Cyrus; Garcia-Manero Guillermo; Patel Jay; Wadleigh Martha; Malinge Sebastien; Yao JinJuan; Kilpivaara Outi; Bhat Rukhmi; Huberman Kety; Thomas Sabrena; Dolgalev Igor; Heguy Adriana; Paietta Elisabeth; Le Beau Michelle M; Beran Miloslav; Tallman Martin S; Ebert Benjamin L; Kantarjian Hagop M; Stone Richard M; Gilliland D Gary; Crispino John D; Levine Ross L
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
Blood 2009;114(1):144-7.
2009: Hofmann Inga; Stover Elizabeth H; Cullen Dana E; Mao Junhao; Morgan Kelly J; Lee Benjamin H; Kharas Michael G; Miller Peter G; Cornejo Melanie G; Okabe Rachel; Armstrong Scott A; Ghilardi Nico; Gould Stephen; de Sauvage Frederic J; McMahon Andrew P; Gilliland D Gary
Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis.
Cell stem cell 2009;4(6):559-67.
2009: Scholl Claudia; Fröhling Stefan; Dunn Ian F; Schinzel Anna C; Barbie David A; Kim So Young; Silver Serena J; Tamayo Pablo; Wadlow Raymond C; Ramaswamy Sridhar; Döhner Konstanze; Bullinger Lars; Sandy Peter; Boehm Jesse S; Root David E; Jacks Tyler; Hahn William C; Gilliland D Gary
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.
Cell 2009;137(5):821-34.
2009: Tefferi A; Pardanani A; Lim K-H; Abdel-Wahab O; Lasho T L; Patel J; Gangat N; Finke C M; Schwager S; Mullally A; Li C-Y; Hanson C A; Mesa R; Bernard O; Delhommeau F; Vainchenker W; Gilliland D G; Levine R L
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(5):905-11.
2009: Tefferi A; Levine R L; Lim K-H; Abdel-Wahab O; Lasho T L; Patel J; Finke C M; Mullally A; Li C-Y; Pardanani A; Gilliland D G
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(5):900-4.
2009: Kilpivaara Outi; Mukherjee Semanti; Schram Alison M; Wadleigh Martha; Mullally Ann; Ebert Benjamin L; Bass Adam; Marubayashi Sachie; Heguy Adriana; Garcia-Manero Guillermo; Kantarjian Hagop; Offit Kenneth; Stone Richard M; Gilliland D Gary; Klein Robert J; Levine Ross L
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.
Nature genetics 2009;41(4):455-9.
2009: Mercher Thomas; Raffel Glen D; Moore Sandra A; Cornejo Melanie G; Baudry-Bluteau Dominique; Cagnard Nicolas; Jesneck Jonathan L; Pikman Yana; Cullen Dana; Williams Ifor R; Akashi Koichi; Shigematsu Hirokazu; Bourquin Jean-Pierre; Giovannini Marco; Vainchenker William; Levine Ross L; Lee Benjamin H; Bernard Olivier A; Gilliland D Gary
The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model.
The Journal of clinical investigation 2009;119(4):852-64.
2009: Tothova Zuzana; Gilliland D Gary
A radical bailout strategy for cancer stem cells.
Cell stem cell 2009;4(3):196-7.
2009: Cornejo Melanie G; Kharas Michael G; Werneck Miriam B; Le Bras Séverine; Moore Sandra A; Ball Brian; Beylot-Barry Marie; Rodig Scott J; Aster Jon C; Lee Benjamin H; Cantor Harvey; Merlio Jean-Philippe; Gilliland D Gary; Mercher Thomas
Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models.
Blood 2009;113(12):2746-54.
2009: Tyner Jeffrey W; Erickson Heidi; Deininger Michael W N; Willis Stephanie G; Eide Christopher A; Levine Ross L; Heinrich Michael C; Gattermann Norbert; Gilliland D Gary; Druker Brian J; Loriaux Marc M
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.
Blood 2009;113(8):1749-55.
2009: Bernard L; Belisle C; Mollica L; Provost S; Roy D-C; Gilliland D G; Levine R L; Busque L
Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(2):287-91.
2009: Raffel Glen D; Chu Gerald C; Jesneck Jonathan L; Cullen Dana E; Bronson Roderick T; Bernard Olivier A; Gilliland D Gary
Ott1 (Rbm15) is essential for placental vascular branching morphogenesis and embryonic development of the heart and spleen.
Molecular and cellular biology 2009;29(2):333-41.
2008: Kawamata Norihiko; Ogawa Seishi; Yamamoto Go; Lehmann Soren; Levine Ross L; Pikman Yana; Nannya Yasuhito; Sanada Masashi; Miller Carl W; Gilliland D Gary; Koeffler H Phillip
Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray.
Experimental hematology 2008;36(11):1471-9.
2008: George Rani E; Sanda Takaomi; Hanna Megan; Fröhling Stefan; Luther William; Zhang Jianming; Ahn Yebin; Zhou Wenjun; London Wendy B; McGrady Patrick; Xue Liquan; Zozulya Sergey; Gregor Vlad E; Webb Thomas R; Gray Nathanael S; Gilliland D Gary; Diller Lisa; Greulich Heidi; Morris Stephan W; Meyerson Matthew; Look A Thomas
Activating mutations in ALK provide a therapeutic target in neuroblastoma.
Nature 2008;455(7215):975-8.
2008: Kalaitzidis Demetrios; Gilliland D Gary
Going with the flow: JAK-STAT signaling in JMML.
Cancer cell 2008;14(4):279-80.
2008: Kindler Thomas; Cornejo Melanie G; Scholl Claudia; Liu Jianing; Leeman Dena S; Haydu J Erika; Fröhling Stefan; Lee Benjamin H; Gilliland D Gary
K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors.
Blood 2008;112(8):3373-82.
2008: Mercher Thomas; Cornejo Melanie G; Sears Christopher; Kindler Thomas; Moore Sandra A; Maillard Ivan; Pear Warren S; Aster Jon C; Gilliland D Gary
Notch signaling specifies megakaryocyte development from hematopoietic stem cells.
Cell stem cell 2008;3(3):314-26.
2008: Levine Ross L; Gilliland D Gary
Myeloproliferative disorders.
Blood 2008;112(6):2190-8.
2008: Tam Winnie F; Gu Ting-Lei; Chen Jing; Lee Benjamin H; Bullinger Lars; Fröhling Stefan; Wang Andrew; Monti Stefano; Golub Todd R; Gilliland D Gary
Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells.
Blood 2008;112(5):1981-92.
2008: Scholl Claudia; Gilliland D Gary; Fröhling Stefan
Deregulation of signaling pathways in acute myeloid leukemia.
Seminars in oncology 2008;35(4):336-45.
2008: De Keersmaecker Kim; Rocnik Jennifer L; Bernad Rafael; Lee Benjamin H; Leeman Dena; Gielen Olga; Verachtert Hanne; Folens Cedric; Munck Sebastian; Marynen Peter; Fornerod Maarten; Gilliland D Gary; Cools Jan
Kinase activation and transformation by NUP214-ABL1 is dependent on the context of the nuclear pore.
Molecular cell 2008;31(1):134-42.
2008: Meshinchi Soheil; Stirewalt Derek L; Alonzo Todd A; Boggon Titus J; Gerbing Robert B; Rocnik Jennifer L; Lange Beverly J; Gilliland D Gary; Radich Jerald P
Structural and numerical variation of FLT3/ITD in pediatric AML.
Blood 2008;111(10):4930-3.
2008: Loriaux Marc M; Levine Ross L; Tyner Jeffrey W; Fröhling Stefan; Scholl Claudia; Stoffregen Eric P; Wernig Gerlinde; Erickson Heidi; Eide Christopher A; Berger Roland; Bernard Olivier A; Griffin James D; Stone Richard M; Lee Benjamin; Meyerson Matthew; Heinrich Michael C; Deininger Michael W; Gilliland D Gary; Druker Brian J
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia.
Blood 2008;111(9):4788-96.
2008: Wernig Gerlinde; Kharas Michael G; Okabe Rachel; Moore Sandra A; Leeman Dena S; Cullen Dana E; Gozo Maricel; McDowell Elizabeth P; Levine Ross L; Doukas John; Mak Chi Ching; Noronha Glenn; Martin Michael; Ko Yon D; Lee Benjamin H; Soll Richard M; Tefferi Ayalew; Hood John D; Gilliland D Gary
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.
Cancer cell 2008;13(4):311-20.
2008: Wernig Gerlinde; Gonneville Jeffrey R; Crowley Brian J; Rodrigues Margret S; Reddy Mamatha M; Hudon Heidi E; Walz Christoph; Reiter Andreas; Podar Klaus; Royer Yohan; Constantinescu Stefan N; Tomasson Michael H; Griffin James D; Gilliland D Gary; Sattler Martin
The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.
Blood 2008;111(7):3751-9.
2008: Swanson Kenneth D; Winter Jordan M; Reis Marcelo; Bentires-Alj Mohamed; Greulich Heidi; Grewal Rupinder; Hruban Ralph H; Yeo Charles J; Yassin Yosuf; Iartchouk Oleg; Montgomery Kate; Whitman Susan P; Caligiuri Michael A; Loh Mignon L; Gilliland D Gary; Look A Thomas; Kucherlapati Raju; Kern Scott E; Meyerson Matthew; Neel Benjamin G
SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients.
Genes, chromosomes & cancer 2008;47(3):253-9.
2008: Pardanani Animesh; Fridley Brooke L; Lasho Terra L; Gilliland D Gary; Tefferi Ayalew
Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders.
Blood 2008;111(5):2785-9.
2008: Huang Gang; Zhang Pu; Hirai Hideyo; Elf Shannon; Yan Xiaomei; Chen Zhao; Koschmieder Steffen; Okuno Yutaka; Dayaram Tajhal; Growney Joseph D; Shivdasani Ramesh A; Gilliland D Gary; Speck Nancy A; Nimer Stephen D; Tenen Daniel G
PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis.
Nature genetics 2008;40(1):51-60.
2008: Morgan Kelly; Kharas Michael; Dzierzak Elaine; Gilliland D Gary
Isolation of early hematopoietic stem cells from murine yolk sac and AGM.
Journal of visualized experiments : JoVE 2008;(16):.
2008: Morgan Kelly J; Gilliland D Gary
A role for JAK2 mutations in myeloproliferative diseases.
Annual review of medicine 2008;59():213-22.
2007: Fröhling Stefan; Scholl Claudia; Levine Ross L; Loriaux Marc; Boggon Titus J; Bernard Olivier A; Berger Roland; Döhner Hartmut; Döhner Konstanze; Ebert Benjamin L; Teckie Sewit; Golub Todd R; Jiang Jingrui; Schittenhelm Marcus M; Lee Benjamin H; Griffin James D; Stone Richard M; Heinrich Michael C; Deininger Michael W; Druker Brian J; Gilliland D Gary
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.
Cancer cell 2007;12(6):501-13.
2007: Barry Elly V; Clark Jennifer J; Cools Jan; Roesel Johannes; Gilliland D Gary
Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin.
Blood 2007;110(13):4476-9.
2007: Lee Benjamin H; Tothova Zuzana; Levine Ross L; Anderson Kristina; Buza-Vidas Natalija; Cullen Dana E; McDowell Elizabeth P; Adelsperger Jennifer; Fröhling Stefan; Huntly Brian J P; Beran Miloslav; Jacobsen Sten Eirik; Gilliland D Gary
FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.
Cancer cell 2007;12(4):367-80.
2007: Kang Sumin; Dong Shaozhong; Gu Ting-Lei; Guo Ailan; Cohen Michael S; Lonial Sagar; Khoury Hanna Jean; Fabbro Doriano; Gilliland D Gary; Bergsagel P Leif; Taunton Jack; Polakiewicz Roberto D; Chen Jing
FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway.
Cancer cell 2007;12(3):201-14.
2007: Levine Ross L; Pardanani Animesh; Tefferi Ayalew; Gilliland D Gary
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.
Nature reviews. Cancer 2007;7(9):673-83.
2007: Pardanani Animesh; Lasho Terra L; Finke Christy; Mesa Ruben A; Hogan William J; Ketterling Rhett P; Gilliland Dwight Gary; Tefferi Ayalew
Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes.
Stem cells (Dayton, Ohio) 2007;25(9):2358-62.
2007: Tothova Zuzana; Gilliland D Gary
FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system.
Cell stem cell 2007;1(2):140-52.
2007: Pardanani A; Hood J; Lasho T; Levine R L; Martin M B; Noronha G; Finke C; Mak C C; Mesa R; Zhu H; Soll R; Gilliland D G; Tefferi A
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(8):1658-68.
2007: Tefferi Ayalew; Thiele Juergen; Orazi Attilio; Kvasnicka Hans Michael; Barbui Tiziano; Hanson Curtis A; Barosi Giovanni; Verstovsek Srdan; Birgegard Gunnar; Mesa Ruben; Reilly John T; Gisslinger Heinz; Vannucchi Alessandro M; Cervantes Francisco; Finazzi Guido; Hoffman Ronald; Gilliland D Gary; Bloomfield Clara D; Vardiman James W
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.
Blood 2007;110(4):1092-7.
2007: Yamamoto Go; Nannya Yasuhito; Kato Motohiro; Sanada Masashi; Levine Ross L; Kawamata Norihiko; Hangaishi Akira; Kurokawa Mineo; Chiba Shigeru; Gilliland D Gary; Koeffler H Phillip; Ogawa Seishi
Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays.
American journal of human genetics 2007;81(1):114-26.
2007: Gu Ting-lei; Mercher Thomas; Tyner Jeffrey W; Goss Valerie L; Walters Denise K; Cornejo Melanie G; Reeves Cynthia; Popova Lana; Lee Kimberly; Heinrich Michael C; Rush John; Daibata Masanori; Miyoshi Isao; Gilliland D Gary; Druker Brian J; Polakiewicz Roberto D
A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia.
Blood 2007;110(1):323-33.
2007: Raffel Glen D; Mercher Thomas; Shigematsu Hirokazu; Williams Ifor R; Cullen Dana E; Akashi Koichi; Bernard Olivier A; Gilliland D Gary
Ott1(Rbm15) has pleiotropic roles in hematopoietic development.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(14):6001-6.
2007: Scholl Claudia; Bansal Dimple; Döhner Konstanze; Eiwen Karina; Huntly Brian J P; Lee Benjamin H; Rücker Frank G; Schlenk Richard F; Bullinger Lars; Döhner Hartmut; Gilliland D Gary; Fröhling Stefan
The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis.
The Journal of clinical investigation 2007;117(4):1037-48.
2007: Tefferi Ayalew; Gilliland D Gary
Oncogenes in myeloproliferative disorders.
Cell cycle (Georgetown, Tex.) 2007;6(5):550-66.
2007: Klose Robert J; Yan Qin; Tothova Zuzana; Yamane Kenichi; Erdjument-Bromage Hediye; Tempst Paul; Gilliland D Gary; Zhang Yi; Kaelin William G
The retinoblastoma binding protein RBP2 is an H3K4 demethylase.
Cell 2007;128(5):889-900.
2007: Scott Linda M; Tong Wei; Levine Ross L; Scott Mike A; Beer Philip A; Stratton Michael R; Futreal P Andrew; Erber Wendy N; McMullin Mary Frances; Harrison Claire N; Warren Alan J; Gilliland D Gary; Lodish Harvey F; Green Anthony R
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
The New England journal of medicine 2007;356(5):459-68.
2007: Ihle James N; Gilliland D Gary
Jak2: normal function and role in hematopoietic disorders.
Current opinion in genetics & development 2007;17(1):8-14.
2007: Tothova Zuzana; Kollipara Ramya; Huntly Brian J; Lee Benjamin H; Castrillon Diego H; Cullen Dana E; McDowell Elizabeth P; Lazo-Kallanian Suzan; Williams Ifor R; Sears Christopher; Armstrong Scott A; Passegué Emmanuelle; DePinho Ronald A; Gilliland D Gary
FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress.
Cell 2007;128(2):325-39.
2007: Paik Ji-Hye; Kollipara Ramya; Chu Gerald; Ji Hongkai; Xiao Yonghong; Ding Zhihu; Miao Lili; Tothova Zuzana; Horner James W; Carrasco Daniel R; Jiang Shan; Gilliland D Gary; Chin Lynda; Wong Wing H; Castrillon Diego H; DePinho Ronald A
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis.
Cell 2007;128(2):309-23.
2007: Levine Ross L; Gilliland D Gary
JAK-2 mutations and their relevance to myeloproliferative disease.
Current opinion in hematology 2007;14(1):43-7.
2006: Lasho Terra L; Pardanani Animesh; McClure Rebecca F; Mesa Ruben A; Levine Ross L; Gilliland D Gary; Tefferi Ayalew
Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time.
British journal of haematology 2006;135(5):683-7.
2006: Bansal Dimple; Scholl Claudia; Fröhling Stefan; McDowell Elizabeth; Lee Benjamin H; Döhner Konstanze; Ernst Patricia; Davidson Alan J; Daley George Q; Zon Leonard I; Gilliland D Gary; Huntly Brian J P
Cdx4 dysregulates Hox gene expression and generates acute myeloid leukemia alone and in cooperation with Meis1a in a murine model.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(45):16924-9.
2006: Pardanani Animesh D; Levine Ross L; Lasho Terra; Pikman Yana; Mesa Ruben A; Wadleigh Martha; Steensma David P; Elliott Michelle A; Wolanskyj Alexandra P; Hogan William J; McClure Rebecca F; Litzow Mark R; Gilliland D Gary; Tefferi Ayalew
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.
Blood 2006;108(10):3472-6.
2006: Mercher Thomas; Wernig Gerlinde; Moore Sandra A; Levine Ross L; Gu Ting-Lei; Fröhling Stefan; Cullen Dana; Polakiewicz Roberto D; Bernard Olivier A; Boggon Titus J; Lee Benjamin H; Gilliland D Gary
JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.
Blood 2006;108(8):2770-9.
2006: Tefferi Ayalew; Barosi Giovanni; Mesa Ruben A; Cervantes Francisco; Deeg H Joachim; Reilly John T; Verstovsek Srdan; Dupriez Brigitte; Silver Richard T; Odenike Olatoyosi; Cortes Jorge; Wadleigh Martha; Solberg Lawrence A; Camoriano John K; Gisslinger Heinz; Noel Pierre; Thiele Juergen; Vardiman James W; Hoffman Ronald; Cross Nicholas C P; Gilliland D Gary; Kantarjian Hagop;
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
Blood 2006;108(5):1497-503.
2006: Chan Iris T; Kutok Jeffery L; Williams Ifor R; Cohen Sarah; Moore Sandra; Shigematsu Hirokazu; Ley Timothy J; Akashi Koichi; Le Beau Michelle M; Gilliland D Gary
Oncogenic K-ras cooperates with PML-RAR alpha to induce an acute promyelocytic leukemia-like disease.
Blood 2006;108(5):1708-15.
2006: Krivtsov Andrei V; Twomey David; Feng Zhaohui; Stubbs Matthew C; Wang Yingzi; Faber Joerg; Levine Jason E; Wang Jing; Hahn William C; Gilliland D Gary; Golub Todd R; Armstrong Scott A
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.
Nature 2006;442(7104):818-22.
2006: Rocnik Jennifer L; Okabe Rachel; Yu Jin-Chen; Lee Benjamin H; Giese Neill; Schenkein David P; Gilliland D Gary
Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.
Blood 2006;108(4):1339-45.
2006: Walters Denise K; Mercher Thomas; Gu Ting-Lei; O'Hare Thomas; Tyner Jeffrey W; Loriaux Marc; Goss Valerie L; Lee Kimberly A; Eide Christopher A; Wong Matthew J; Stoffregen Eric P; McGreevey Laura; Nardone Julie; Moore Sandra A; Crispino John; Boggon Titus J; Heinrich Michael C; Deininger Michael W; Polakiewicz Roberto D; Gilliland D Gary; Druker Brian J
Activating alleles of JAK3 in acute megakaryoblastic leukemia.
Cancer cell 2006;10(1):65-75.
2006: Rocnik Jennifer L; Gilliland D Gary
Cell-autonomous and -nonautonomous contributions of STAT1 in murine models of tumorigenesis.
Cancer cell 2006;10(1):1-2.
2006: Pikman Yana; Lee Benjamin H; Mercher Thomas; McDowell Elizabeth; Ebert Benjamin L; Gozo Maricel; Cuker Adam; Wernig Gerlinde; Moore Sandra; Galinsky Ilene; DeAngelo Daniel J; Clark Jennifer J; Lee Stephanie J; Golub Todd R; Wadleigh Martha; Gilliland D Gary; Levine Ross L
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
PLoS medicine 2006;3(7):e270.
2006: Loh Mignon L; Goldwasser Meredith A; Silverman Lewis B; Poon Wing-Man; Vattikuti Shashaank; Cardoso Angelo; Neuberg Donna S; Shannon Kevin M; Sallan Stephen E; Gilliland D Gary
Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01.
Blood 2006;107(11):4508-13.
2006: Wernig Gerlinde; Mercher Thomas; Okabe Rachel; Levine Ross L; Lee Benjamin H; Gilliland D Gary
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.
Blood 2006;107(11):4274-81.
2006: Stover Elizabeth H; Chen Jing; Folens Cedric; Lee Benjamin H; Mentens Nicole; Marynen Peter; Williams Ifor R; Gilliland D Gary; Cools Jan
Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(21):8078-83.
2006: Levine Ross L; Belisle Claude; Wadleigh Martha; Zahrieh David; Lee Stephanie; Chagnon Pierre; Gilliland D Gary; Busque Lambert
X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis.
Blood 2006;107(10):4139-41.
2006: Wagner Katharina; Zhang Pu; Rosenbauer Frank; Drescher Bettina; Kobayashi Susumu; Radomska Hanna S; Kutok Jeffery L; Gilliland D Gary; Krauter Jürgen; Tenen Daniel G
Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(16):6338-43.
2006: Radomska Hanna S; Bassères Daniela S; Zheng Rui; Zhang Pu; Dayaram Tajhal; Yamamoto Yukiya; Sternberg David W; Lokker Nathalie; Giese Neill A; Bohlander Stefan K; Schnittger Susanne; Delmotte Marie-Hélène; Davis Roger J; Small Donald; Hiddemann Wolfgang; Gilliland D Gary; Tenen Daniel G
Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations.
The Journal of experimental medicine 2006;203(2):371-81.
2006: Fröhling Stefan; Lipka Daniel B; Kayser Sabine; Scholl Claudia; Schlenk Richard F; Döhner Hartmut; Gilliland D Gary; Levine Ross L; Döhner Konstanze
Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7.
Blood 2006;107(3):1242-3.
2006: Tefferi Ayalew; Lasho Terra L; Schwager Susan M; Strand Jacob S; Elliott Michelle; Mesa Ruben; Li Chin-Yang; Wadleigh Martha; Lee Stephanie J; Gilliland D Gary
The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera.
Cancer 2006;106(3):631-5.
2006: Gotlib Jason; Cross N C P; Gilliland D Gary
Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy.
Best practice & research. Clinical haematology 2006;19(3):535-69.
2006: Cools Jan; Stover Elizabeth H; Gilliland D Gary
Detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia.
Methods in molecular medicine 2006;125():177-87.
2005: Lu Xiaohui; Levine Ross; Tong Wei; Wernig Gerlinde; Pikman Yana; Zarnegar Sara; Gilliland D Gary; Lodish Harvey
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(52):18962-7.
2005: Chen Jing; Lee Benjamin H; Williams Ifor R; Kutok Jeffery L; Mitsiades Constantine S; Duclos Nicole; Cohen Sarah; Adelsperger Jennifer; Okabe Rachel; Coburn Allison; Moore Sandra; Huntly Brian J P; Fabbro Doriano; Anderson Kenneth C; Griffin James D; Gilliland Dwight Gary
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies.
Oncogene 2005;24(56):8259-67.
2005: Lee Benjamin H; Williams Ifor R; Anastasiadou Ema; Boulton Christina L; Joseph Sarah W; Amaral Sonia M; Curley David P; Duclos Nicole; Huntly Brian J P; Fabbro Doriano; Griffin James D; Gilliland Dwight Gary
FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model.
Oncogene 2005;24(53):7882-92.
2005: Levine Ross L; Loriaux Marc; Huntly Brian J P; Loh Mignon L; Beran Miroslav; Stoffregen Eric; Berger Roland; Clark Jennifer J; Willis Stephanie G; Nguyen Kim T; Flores Nikki J; Estey Elihu; Gattermann Norbert; Armstrong Scott; Look A Thomas; Griffin James D; Bernard Olivier A; Heinrich Michael C; Gilliland D Gary; Druker Brian; Deininger Michael W N
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.
Blood 2005;106(10):3377-9.
2005: Stover Elizabeth H; Chen Jing; Lee Benjamin H; Cools Jan; McDowell Elizabeth; Adelsperger Jennifer; Cullen Dana; Coburn Allison; Moore Sandra A; Okabe Rachel; Fabbro Doriano; Manley Paul W; Griffin James D; Gilliland D Gary
The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.
Blood 2005;106(9):3206-13.
2005: Wolanskyj Alexandra P; Lasho Terra L; Schwager Susan M; McClure Rebecca F; Wadleigh Martha; Lee Stephanie J; Gilliland D Gary; Tefferi Ayalew
JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.
British journal of haematology 2005;131(2):208-13.
2005: Tefferi Ayalew; Sirhan Shireen; Lasho Terra L; Schwager Susan M; Li Chin-Yang; Dingli David; Wolanskyj Alexandra P; Steensma David P; Mesa Ruben; Gilliland D G
Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.
British journal of haematology 2005;131(2):166-71.
2005: Gotlib Jason; Berubé Caroline; Growney Joseph D; Chen Ching-Cheng; George Tracy I; Williams Christopher; Kajiguchi Tomohiro; Ruan Jia; Lilleberg Stan L; Durocher Jeffrey A; Lichy Jack H; Wang Yanfeng; Cohen Pamela S; Arber Daniel A; Heinrich Michael C; Neckers Len; Galli Stephen J; Gilliland D Gary; Coutré Steven E
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.
Blood 2005;106(8):2865-70.
2005: Fröhling Stefan; Scholl Claudia; Gilliland D Gary; Levine Ross L
Genetics of myeloid malignancies: pathogenetic and clinical implications.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(26):6285-95.
2005: Lasho Terra L; Mesa Ruben; Gilliland D Gary; Tefferi Ayalew
Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes.
British journal of haematology 2005;130(5):797-9.
2005: Tefferi Ayalew; Gilliland D Gary
JAK2 in myeloproliferative disorders is not just another kinase.
Cell cycle (Georgetown, Tex.) 2005;4(8):1053-6.
2005: Tallman Martin S; Gilliland D Gary; Rowe Jacob M
Drug therapy for acute myeloid leukemia.
Blood 2005;106(4):1154-63.
2005: Steensma David P; Dewald Gordon W; Lasho Terra L; Powell Heather L; McClure Rebecca F; Levine Ross L; Gilliland D Gary; Tefferi Ayalew
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.
Blood 2005;106(4):1207-9.
2005: Tefferi Ayalew; Gilliland D Gary
The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis.
Mayo Clinic proceedings. Mayo Clinic 2005;80(7):947-58.
2005: Growney Joseph D; Clark Jennifer J; Adelsperger Jennifer; Stone Richard; Fabbro Doriano; Griffin James D; Gilliland D Gary
Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
Blood 2005;106(2):721-4.
2005: Chen Jing; Williams Ifor R; Lee Benjamin H; Duclos Nicole; Huntly Brian J P; Donoghue Daniel J; Gilliland D Gary
Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation.
Blood 2005;106(1):328-37.
2005: Growney Joseph D; Shigematsu Hirokazu; Li Zhe; Lee Benjamin H; Adelsperger Jennifer; Rowan Rebecca; Curley David P; Kutok Jeffery L; Akashi Koichi; Williams Ifor R; Speck Nancy A; Gilliland D Gary
Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype.
Blood 2005;106(2):494-504.
2005: Huntly Brian J P; Gilliland D Gary
Cancer biology: summing up cancer stem cells.
Nature 2005;435(7046):1169-70.
2005: Levine Ross L; Wadleigh Martha; Cools Jan; Ebert Benjamin L; Wernig Gerlinde; Huntly Brian J P; Boggon Titus J; Wlodarska Iwona; Clark Jennifer J; Moore Sandra; Adelsperger Jennifer; Koo Sumin; Lee Jeffrey C; Gabriel Stacey; Mercher Thomas; D'Andrea Alan; Fröhling Stefan; Döhner Konstanze; Marynen Peter; Vandenberghe Peter; Mesa Ruben A; Tefferi Ayalew; Griffin James D; Eck Michael J; Sellers William R; Meyerson Matthew; Golub Todd R; Lee Stephanie J; Gilliland D Gary
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Cancer cell 2005;7(4):387-97.
2005: Huntly Brian J P; Gilliland D Gary
Leukaemia stem cells and the evolution of cancer-stem-cell research.
Nature reviews. Cancer 2005;5(4):311-21.
2005: Clark Jennifer; Cools Jan; Gilliland D Gary
EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head.
PLoS medicine 2005;2(3):e75.
2005: Mohi M Golam; Williams Ifor R; Dearolf Charles R; Chan Gordon; Kutok Jeffery L; Cohen Sarah; Morgan Kelly; Boulton Christina; Shigematsu Hirokazu; Keilhack Heike; Akashi Koichi; Gilliland D Gary; Neel Benjamin G
Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations.
Cancer cell 2005;7(2):179-91.
2005: Weisberg Ellen; Manley Paul W; Breitenstein Werner; Brüggen Josef; Cowan-Jacob Sandra W; Ray Arghya; Huntly Brian; Fabbro Doriano; Fendrich Gabriele; Hall-Meyers Elizabeth; Kung Andrew L; Mestan Jürgen; Daley George Q; Callahan Linda; Catley Laurie; Cavazza Cara; Azam Mohammad; Neuberg Donna; Wright Renee D; Gilliland D Gary; Griffin James D
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.
Cancer cell 2005;7(2):129-41.
2005: Unwin Richard D; Sternberg David W; Lu Yuning; Pierce Andrew; Gilliland D Gary; Whetton Anthony D
Global effects of BCR/ABL and TEL/PDGFRbeta expression on the proteome and phosphoproteome: identification of the Rho pathway as a target of BCR/ABL.
The Journal of biological chemistry 2005;280(8):6316-26.
2005: Levine R L; Wadleigh M; Sternberg D W; Wlodarska I; Galinsky I; Stone R M; DeAngelo D J; Gilliland D Gary; Cools J
KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32).
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(1):27-30.
2005: Stone Richard M; DeAngelo Daniel J; Klimek Virginia; Galinsky Ilene; Estey Eli; Nimer Stephen D; Grandin Wilson; Lebwohl David; Wang Yanfeng; Cohen Pamela; Fox Edward A; Neuberg Donna; Clark Jennifer; Gilliland D Gary; Griffin James D
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.
Blood 2005;105(1):54-60.
2005: Gilliland D Gary; Fagan Tom
Your health in the 21st century. Do stem cells cause cancer?
Newsweek 2005;145(26A):20.
2004: Huntly Brian J P; Shigematsu Hirokazu; Deguchi Kenji; Lee Benjamin H; Mizuno Shinichi; Duclos Nicky; Rowan Rebecca; Amaral Sonia; Curley David; Williams Ifor R; Akashi Koichi; Gilliland D Gary
MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors.
Cancer cell 2004;6(6):587-96.
2004: Gilliland Dwight Gary
FLT3 Inhibitors in the Treatment of AML.
Clinical advances in hematology & oncology : H&O 2004;2(11):708-10.
2004: Clark Jennifer J; Cools Jan; Curley David P; Yu Jin-Chen; Lokker Nathalie A; Giese Neill A; Gilliland D Gary
Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.
Blood 2004;104(9):2867-72.
2004: Chen Jing; Deangelo Daniel J; Kutok Jeffery L; Williams Ifor R; Lee Benjamin H; Wadleigh Martha; Duclos Nicole; Cohen Sarah; Adelsperger Jennifer; Okabe Rachel; Coburn Allison; Galinsky Ilene; Huntly Brian; Cohen Pamela S; Meyer Thomas; Fabbro Doriano; Roesel Johannes; Banerji Lolita; Griffin James D; Xiao Sheng; Fletcher Jonathan A; Stone Richard M; Gilliland D Gary
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(40):14479-84.
2004: Graux C; Cools J; Melotte C; Quentmeier H; Ferrando A; Levine R; Vermeesch J R; Stul M; Dutta B; Boeckx N; Bosly A; Heimann P; Uyttebroeck A; Mentens N; Somers R; MacLeod R A F; Drexler H G; Look A T; Gilliland D G; Michaux L; Vandenberghe P; Wlodarska I; Marynen Peter; Hagemeijer Anne
Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia.
Nature genetics 2004;36(10):1084-9.
2004: Huntly Brian J P; Gilliland D Gary
Blasts from the past: new lessons in stem cell biology from chronic myelogenous leukemia.
Cancer cell 2004;6(3):199-201.
2004: Cools Jan; Mentens Nicole; Furet Pascal; Fabbro Doriano; Clark Jennifer J; Griffin James D; Marynen Peter; Gilliland D Gary
Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia.
Cancer research 2004;64(18):6385-9.
2004: Jiang Jingrui; Paez J Guillermo; Lee Jeffrey C; Bo Ronghai; Stone Richard M; DeAngelo Daniel J; Galinsky Ilene; Wolpin Brian M; Jonasova Anna; Herman Paula; Fox Edward A; Boggon Titus J; Eck Michael J; Weisberg Ellen; Griffin James D; Gilliland D Gary; Meyerson Matthew; Sellers William R
Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.
Blood 2004;104(6):1855-8.
2004: Araki Toshiyuki; Mohi M Golam; Ismat Fraz A; Bronson Roderick T; Williams Ifor R; Kutok Jeffery L; Yang Wentian; Pao Lily I; Gilliland D Gary; Epstein Jonathan A; Neel Benjamin G
Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation.
Nature medicine 2004;10(8):849-57.
2004: Chen Jing; Williams Ifor R; Kutok Jeffery L; Duclos Nicole; Anastasiadou Ema; Masters Shane C; Fu Haian; Gilliland D Gary
Positive and negative regulatory roles of the WW-like domain in TEL-PDGFbetaR transformation.
Blood 2004;104(2):535-42.
2004: Chen Jing; Wall Nathan R; Kocher Kerry; Duclos Nicole; Fabbro Doriano; Neuberg Donna; Griffin James D; Shi Yang; Gilliland D Gary
Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin.
The Journal of clinical investigation 2004;113(12):1784-91.
2004: Gu Ting-Lei; Tothova Zuzana; Scheijen Blanca; Griffin James D; Gilliland D Gary; Sternberg David W
NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a.
Blood 2004;103(12):4622-9.
2004: Chan Iris T; Gilliland D Gary
Oncogenic K-ras in mouse models of myeloproliferative disease and acute myeloid leukemia.
Cell cycle (Georgetown, Tex.) 2004;3(5):536-7.
2004: Stone Richard M; Gilliland D Gary; Klion Amy D
Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome.
Seminars in oncology 2004;31(2 Suppl 6):12-7.
2004: Gotlib Jason; Cools Jan; Malone James M; Schrier Stanley L; Gilliland D Gary; Coutré Steven E
The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.
Blood 2004;103(8):2879-91.
2004: Cools Jan; Quentmeier Hilmar; Huntly Brian J P; Marynen Peter; Griffin James D; Drexler Hans G; Gilliland D Gary
The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.
Blood 2004;103(7):2802-5.
2004: Mohi M Golam; Boulton Christina; Gu Ting-Lei; Sternberg David W; Neuberg Donna; Griffin James D; Gilliland D Gary; Neel Benjamin G
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(9):3130-5.
2004: Chan Iris T; Kutok Jeffery L; Williams Ifor R; Cohen Sarah; Kelly Lauren; Shigematsu Hirokazu; Johnson Leisa; Akashi Koichi; Tuveson David A; Jacks Tyler; Gilliland D Gary
Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.
The Journal of clinical investigation 2004;113(4):528-38.
2004: Sternberg David W; Gilliland D Gary
The role of signal transducer and activator of transcription factors in leukemogenesis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(2):361-71.
2004: Cools Jan; Stover Elizabeth H; Wlodarska Iwona; Marynen Peter; Gilliland D Gary
The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia.
Current opinion in hematology 2004;11(1):51-7.
2004: Gilliland D Gary; Jordan Craig T; Felix Carolyn A
The molecular basis of leukemia.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2004;():80-97.
2004: Stone R M; De Angelo J; Galinsky I; Estey E; Klimek V; Grandin W; Lebwohl D; Yap A; Cohen P; Fox E; Neuberg D; Clark J; Gilliland D G; Griffin J D
PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial.
Annals of hematology 2004;83 Suppl 1():S89-90.
2004: Gilliland D G
Targeted therapies in myeloid leukemias.
Annals of hematology 2004;83 Suppl 1():S75-6.
2003: Pardanani Animesh; Ketterling Rhett P; Brockman Stephanie R; Flynn Heather C; Paternoster Sarah F; Shearer Brandon M; Reeder Terra L; Li Chin-Yang; Cross Nicholas C P; Cools Jan; Gilliland D Gary; Dewald Gordon W; Tefferi Ayalew
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
Blood 2003;102(9):3093-6.
2003: Gilliland D Gary
Proteolytic processing in development and leukemogenesis.
Cell 2003;115(3):248-50.
2003: Gilliland D Gary
FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors.
Best practice & research. Clinical haematology 2003;16(3):409-17.
2003: Klion Amy D; Noel Pierre; Akin Cem; Law Melissa A; Gilliland D Gary; Cools Jan; Metcalfe Dean D; Nutman Thomas B
Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness.
Blood 2003;101(12):4660-6.
2003: Cools Jan; Stover Elizabeth H; Boulton Christina L; Gotlib Jason; Legare Robert D; Amaral Sonia M; Curley David P; Duclos Nicole; Rowan Rebecca; Kutok Jeffery L; Lee Benjamin H; Williams Ifor R; Coutre Steven E; Stone Richard M; DeAngelo Daniel J; Marynen Peter; Manley Paul W; Meyer Thomas; Fabbro Doriano; Neuberg Donna; Weisberg Ellen; Griffin James D; Gilliland D Gary
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease.
Cancer cell 2003;3(5):459-69.
2003: Sohal Jastinder; Phan Vernon T; Chan Philip V; Davis Elizabeth M; Patel Bhumi; Kelly Louise M; Abrams Tinya J; O'Farrell Anne Marie; Gilliland D Gary; Le Beau Michelle M; Kogan Scott C
A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657.
Blood 2003;101(8):3188-97.
2003: Deguchi Kenji; Ayton Paul M; Carapeti Melina; Kutok Jeffery L; Snyder Cynthia S; Williams Ifor R; Cross Nicholas C P; Glass Christopher K; Cleary Michael L; Gilliland D Gary
MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP.
Cancer cell 2003;3(3):259-71.
2003: Cools Jan; DeAngelo Daniel J; Gotlib Jason; Stover Elizabeth H; Legare Robert D; Cortes Jorges; Kutok Jeffrey; Clark Jennifer; Galinsky Ilene; Griffin James D; Cross Nicholas C P; Tefferi Ayalew; Malone James; Alam Rafeul; Schrier Stanley L; Schmid Janet; Rose Michal; Vandenberghe Peter; Verhoef Gregor; Boogaerts Marc; Wlodarska Iwona; Kantarjian Hagop; Marynen Peter; Coutre Steven E; Stone Richard; Gilliland D Gary
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
The New England journal of medicine 2003;348(13):1201-14.
2003: Spiekermann Karsten; Dirschinger Ralf J; Schwab Ruth; Bagrintseva Ksenia; Faber Florian; Buske Christian; Schnittger Susanne; Kelly Louise M; Gilliland D Gary; Hiddemann Wolfgang
The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.
Blood 2003;101(4):1494-504.
2002: Gilliland D Gary
Molecular genetics of human leukemias: new insights into therapy.
Seminars in hematology 2002;39(4 Suppl 3):6-11.
2002: Gilliland D Gary; Griffin James D
The roles of FLT3 in hematopoiesis and leukemia.
Blood 2002;100(5):1532-42.
2002: Speck Nancy A; Gilliland D Gary
Core-binding factors in haematopoiesis and leukaemia.
Nature reviews. Cancer 2002;2(7):502-13.
2002: Gilliland D Gary; Griffin James D
Role of FLT3 in leukemia.
Current opinion in hematology 2002;9(4):274-81.
2002: Weisberg Ellen; Boulton Christina; Kelly Louise M; Manley Paul; Fabbro Doriano; Meyer Thomas; Gilliland D Gary; Griffin James D
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.
Cancer cell 2002;1(5):433-43.
2002: Kelly Louise M; Yu Jin-Chen; Boulton Christina L; Apatira Mutiah; Li Jason; Sullivan Carol M; Williams Ifor; Amaral Sonia M; Curley David P; Duclos Nicole; Neuberg Donna; Scarborough Robert M; Pandey Anjali; Hollenbach Stanley; Abe Keith; Lokker Nathalie A; Gilliland D Gary; Giese Neill A
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).
Cancer cell 2002;1(5):421-32.
2002: Gilliland D Gary; Tallman Martin S
Focus on acute leukemias.
Cancer cell 2002;1(5):417-20.
2002: Kelly Louise M; Kutok Jeffrey L; Williams Ifor R; Boulton Christina L; Amaral Sonia M; Curley David P; Ley Timothy J; Gilliland D Gary
PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(12):8283-8.
2002: Million Ryan P; Aster Jon; Gilliland D Gary; Van Etten Richard A
The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice.
Blood 2002;99(12):4568-77.
2002: Dash Ajeeta B; Williams Ifor R; Kutok Jeffery L; Tomasson Michael H; Anastasiadou Ema; Lindahl Kathleen; Li Shaoguang; Van Etten Richard A; Borrow Julian; Housman David; Druker Brian; Gilliland D Gary
A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(11):7622-7.
2002: Deguchi K; Gilliland D G
Cooperativity between mutations in tyrosine kinases and in hematopoietic transcription factors in AML.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(4):740-4.
2002: Ferrando Adolfo A; Neuberg Donna S; Staunton Jane; Loh Mignon L; Huard Christine; Raimondi Susana C; Behm Fred G; Pui Ching Hon; Downing James R; Gilliland D Gary; Lander Eric S; Golub Todd R; Look A Thomas
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia.
Cancer cell 2002;1(1):75-87.
2002: Kelly Louise; Clark Jennifer; Gilliland D Gary
Comprehensive genotypic analysis of leukemia: clinical and therapeutic implications.
Current opinion in oncology 2002;14(1):10-8.
2002: Kelly Louise M; Liu Qing; Kutok Jeffrey L; Williams Ifor R; Boulton Christina L; Gilliland D Gary
FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.
Blood 2002;99(1):310-8.
2002: Kelly Louise M; Gilliland D Gary
Genetics of myeloid leukemias.
Annual review of genomics and human genetics 2002;3():179-98.
2002: Gilliland D Gary; Gribben John G
Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2002;8(1):9-16.
2001: Sternberg D W; Tomasson M H; Carroll M; Curley D P; Barker G; Caprio M; Wilbanks A; Kazlauskas A; Gilliland D G
The TEL/PDGFbetaR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways.
Blood 2001;98(12):3390-7.
2001: Andreasson P; Schwaller J; Anastasiadou E; Aster J; Gilliland D G
The expression of ETV6/CBFA2 (TEL/AML1) is not sufficient for the transformation of hematopoietic cell lines in vitro or the induction of hematologic disease in vivo.
Cancer genetics and cytogenetics 2001;130(2):93-104.
2001: Schwaller J; Anastasiadou E; Cain D; Kutok J; Wojiski S; Williams I R; LaStarza R; Crescenzi B; Sternberg D W; Andreasson P; Schiavo R; Siena S; Mecucci C; Gilliland D G
H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22).
Blood 2001;97(12):3910-8.
2001: Frantsve J; Schwaller J; Sternberg D W; Kutok J; Gilliland D G
Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation.
Molecular and cellular biology 2001;21(10):3547-57.
2001: Okuda K; Weisberg E; Gilliland D G; Griffin J D
ARG tyrosine kinase activity is inhibited by STI571.
Blood 2001;97(8):2440-8.
2001: Dash A; Gilliland D G
Molecular genetics of acute myeloid leukaemia.
Best practice & research. Clinical haematology 2001;14(1):49-64.
2001: Gilliland D G
The diverse role of the ETS family of transcription factors in cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(3):451-3.
2001: Li S; Gillessen S; Tomasson M H; Dranoff G; Gilliland D G; Van Etten R A
Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL.
Blood 2001;97(5):1442-50.
2001: Tomasson M H; Williams I R; Li S; Kutok J; Cain D; Gillessen S; Dranoff G; Van Etten R A; Gilliland D G
Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3.
Blood 2001;97(5):1435-41.
2000: Loh M L; Samson Y; Motte E; Moreau L A; Dalton V; Waters S; Sallan S E; Gilliland D G
Translocation (2;8)(p12;q24) associated with a cryptic t(12;21)(p13;q22) TEL/AML1 gene rearrangement in a child with acute lymphoblastic leukemia.
Cancer genetics and cytogenetics 2000;122(2):79-82.
2000: Schwaller J; Parganas E; Wang D; Cain D; Aster J C; Williams I R; Lee C K; Gerthner R; Kitamura T; Frantsve J; Anastasiadou E; Loh M L; Levy D E; Ihle J N; Gilliland D G
Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2.
Molecular cell 2000;6(3):693-704.
2000: Wilbanks A M; Mahajan S; Frank D A; Druker B J; Gilliland D G; Carroll M
TEL/PDGFbetaR fusion protein activates STAT1 and STAT5: a common mechanism for transformation by tyrosine kinase fusion proteins.
Experimental hematology 2000;28(5):584-93.
2000: Liu Q; Schwaller J; Kutok J; Cain D; Aster J C; Williams I R; Gilliland D G
Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia.
The EMBO journal 2000;19(8):1827-38.
2000: Tomasson M H; Sternberg D W; Williams I R; Carroll M; Cain D; Aster J C; Ilaria R L; Van Etten R A; Gilliland D G
Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581.
The Journal of clinical investigation 2000;105(4):423-32.
1999: Song W J; Sullivan M G; Legare R D; Hutchings S; Tan X; Kufrin D; Ratajczak J; Resende I C; Haworth C; Hock R; Loh M; Felix C; Roy D C; Busque L; Kurnit D; Willman C; Gewirtz A M; Speck N A; Bushweller J H; Li F P; Gardiner K; Poncz M; Maris J M; Gilliland D G
Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia.
Nature genetics 1999;23(2):166-75.
1999: Ross T S; Gilliland D G
Transforming properties of the Huntingtin interacting protein 1/ platelet-derived growth factor beta receptor fusion protein.
The Journal of biological chemistry 1999;274(32):22328-36.
1999: Tomasson M H; Williams I R; Hasserjian R; Udomsakdi C; McGrath S M; Schwaller J; Druker B; Gilliland D G
TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor.
Blood 1999;93(5):1707-14.
1998: Loh M L; Silverman L B; Young M L; Neuberg D; Golub T R; Sallan S E; Gilliland D G
Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia.
Blood 1998;92(12):4792-7.
1998: Gilliland D G
Molecular genetics of human leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12 Suppl 1():S7-12.
1998: Schwaller J; Frantsve J; Aster J; Williams I R; Tomasson M H; Ross T S; Peeters P; Van Rompaey L; Van Etten R A; Ilaria R; Marynen P; Gilliland D G
Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes.
The EMBO journal 1998;17(18):5321-33.
1998: Wang L C; Swat W; Fujiwara Y; Davidson L; Visvader J; Kuo F; Alt F W; Gilliland D G; Golub T R; Orkin S H
The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow.
Genes & development 1998;12(15):2392-402.
1998: Mach-Pascual S; Legare R D; Lu D; Kroon M; Neuberg D; Tantravahi R; Stone R M; Freedman A S; Nadler L M; Gribben J G; Gilliland D G
Predictive value of clonality assays in patients with non-Hodgkin's lymphoma undergoing autologous bone marrow transplant: a single institution study.
Blood 1998;91(12):4496-503.
1998: Ross T S; Bernard O A; Berger R; Gilliland D G
Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2).
Blood 1998;91(12):4419-26.
1998: Loh M L; McLean T W; Buckley J D; Howells W; Gilliland D G; Smith F O
Lack of TEL/AML1 fusion in pediatric AML: further evidence for lineage specificity of TEL/AML1.
Leukemia research 1998;22(5):461-4.
1998: Busque L; Gilliland D G
X-inactivation analysis in the 1990s: promise and potential problems.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(2):128-35.
1997: Legare R D; Lu D; Gallagher M; Ho C; Tan X; Barker G; Shimizu K; Ohki M; Lenny N; Hiebert S; Gilliland D G
CBFA2, frequently rearranged in leukemia, is not responsible for a familial leukemia syndrome.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(12):2111-9.
1997: Legare R D; Gribben J G; Maragh M; Hermanowski-Vosatka A; Roach S; Tantravahi R; Nadler L M; Gilliland D G
Prediction of therapy-related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma.
American journal of hematology 1997;56(1):45-51.
1997: Wang L C; Kuo F; Fujiwara Y; Gilliland D G; Golub T R; Orkin S H
Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL.
The EMBO journal 1997;16(14):4374-83.
1996: Carroll M; Tomasson M H; Barker G F; Golub T R; Gilliland D G
The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(25):14845-50.
1996: McLean T W; Ringold S; Neuberg D; Stegmaier K; Tantravahi R; Ritz J; Koeffler H P; Takeuchi S; Janssen J W; Seriu T; Bartram C R; Sallan S E; Gilliland D G; Golub T R
TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia.
Blood 1996;88(11):4252-8.
1996: Okuda K; Golub T R; Gilliland D G; Griffin J D
p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines.
Oncogene 1996;13(6):1147-52.
1996: Golub T R; McLean T; Stegmaier K; Carroll M; Tomasson M; Gilliland D G
The TEL gene and human leukemia.
Biochimica et biophysica acta 1996;1288(1):M7-10.
1996: Golub T R; Goga A; Barker G F; Afar D E; McLaughlin J; Bohlander S K; Rowley J D; Witte O N; Gilliland D G
Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia.
Molecular and cellular biology 1996;16(8):4107-16.
1996: Busque L; Mio R; Mattioli J; Brais E; Blais N; Lalonde Y; Maragh M; Gilliland D G
Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age.
Blood 1996;88(1):59-65.
1996: Busque L; Gilliland D G
The PGK-PCR clonality assay (PPCA).
Molecular biotechnology 1996;5(3):275-80.
1996: Ho C Y; Otterud B; Legare R D; Varvil T; Saxena R; DeHart D B; Kohler S E; Aster J C; Dowton S B; Li F P; Leppert M; Gilliland D G
Linkage of a familial platelet disorder with a propensity to develop myeloid malignancies to human chromosome 21q22.1-22.2.
Blood 1996;87(12):5218-24.
1996: Hiebert S W; Sun W; Davis J N; Golub T; Shurtleff S; Buijs A; Downing J R; Grosveld G; Roussell M F; Gilliland D G; Lenny N; Meyers S
The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription.
Molecular and cellular biology 1996;16(4):1349-55.
1996: Golub T R; Barker G F; Stegmaier K; Gilliland D G
Involvement of the TEL gene in hematologic malignancy by diverse molecular genetic mechanisms.
Current topics in microbiology and immunology 1996;211():279-88.
1995: Zhu J; Frosch M P; Busque L; Beggs A H; Dashner K; Gilliland D G; Black P M
Analysis of meningiomas by methylation- and transcription-based clonality assays.
Cancer research 1995;55(17):3865-72.
1995: Sato Y; Suto Y; Pietenpol J; Golub T R; Gilliland D G; Davis E M; Le Beau M M; Roberts J M; Vogelstein B; Rowley J D
TEL and KIP1 define the smallest region of deletions on 12p13 in hematopoietic malignancies.
Blood 1995;86(4):1525-33.
1995: Legare R D; Gilliland D G
Myelodysplastic syndrome.
Current opinion in hematology 1995;2(4):283-92.
1995: Golub T R; Barker G F; Bohlander S K; Hiebert S W; Ward D C; Bray-Ward P; Morgan E; Raimondi S C; Rowley J D; Gilliland D G
Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(11):4917-21.
1995: Busque L; Gilliland D G; Prchal J T; Sieff C A; Weinstein H J; Sokol J M; Belickova M; Wayne A S; Zuckerman K S; Sokol L
Clonality in juvenile chronic myelogenous leukemia.
Blood 1995;85(1):21-30.
1994: Antin J H; Weinstein H J; Guinan E C; McCarthy P; Bierer B E; Gilliland D G; Parsons S K; Ballen K K; Rimm I J; Falzarano G
Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease.
Blood 1994;84(4):1342-8.
1994: Golub T R; Barker G F; Lovett M; Gilliland D G
Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.
Cell 1994;77(2):307-16.
1994: Zhu J; Leon S P; Beggs A H; Busque L; Gilliland D G; Black P M
Human pituitary adenomas show no loss of heterozygosity at the retinoblastoma gene locus.
The Journal of clinical endocrinology and metabolism 1994;78(4):922-7.
1994: Busque L; Zhu J; DeHart D; Griffith B; Willman C; Carroll R; Black P M; Gilliland D G
An expression based clonality assay at the human androgen receptor locus (HUMARA) on chromosome X.
Nucleic acids research 1994;22(4):697-8.
1994: Busque L; Ilaria R; Tantravahi R; Weinstein H; Gilliland D G
Clonality analysis of childhood ALL in remission: no evidence of clonal hematopoiesis.
Leukemia research 1994;18(2):71-7.
1994: Ballen K K; Gilliland D G; Kalish L A; Shulman L N
Bone marrow dysplasia in patients with newly diagnosed acute myelogenous leukemia does not correlate with history of myelodysplasia or with remission rate and survival.
Cancer 1994;73(2):314-21.
1994: Busque L; Gilliland D G
The PGK-PCR clonality assay (PPCA).
Methods in molecular biology (Clifton, N.J.) 1994;31():237-46.
1993: Busque L; Gilliland D G
Clonal evolution in acute myeloid leukemia.
Blood 1993;82(2):337-42.
1992: Blanchard K L; Gilliland D G; Bunn H F
Clonality in myeloproliferative disorders.
The American journal of the medical sciences 1992;304(2):125-30.
1991: Gilliland D G; Blanchard K L; Levy J; Perrin S; Bunn H F
Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(15):6848-52.
1991: Gilliland D G; Blanchard K L; Bunn H F
Clonality in acquired hematologic disorders.
Annual review of medicine 1991;42():491-506.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Gary Gilliland

Research Profile (preview)

Living Beings

Disorders

Chemicals & Drugs

Physiology

Anatomy

Procedures

Phenomena

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Gary Gilliland (preview)

All Publications